3Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients [J].Leukemia,2007,21(2):270-276.
6Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders[J]. Lancet, 2005,365(9464) : 1054-1061.
7James C,Ugo V, Le Couedic JP, et al. A unique ctonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera[J]. Nature,2005,434(7037) :1144-1148.
8Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia,and myeloid metaplasia with myelofibrosis [J]. Cancer Cell,2005,7(4) :387-397.
9Kralovics R,Passamonti F, Buser AS, et at. A gain-of-function mutation of JAK2 in myeloproliferative disorders[J].N Engl J Med, 2005,352(17) :1779-1790.
10Rossi D, Deambrogi C,Capello D, et at. JAK2V617F mutation in leukaemic transformation of philadelphia negative chronic myeloproliferative disorders[J].Blood (ASH Annual Meeting Abstracts), 2006,108 : 3605.
